New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer

References

• Top 20 best-selling drugs of 2012. Genetic engineering & biotechnology news. 2013. Available from: www.genengnews.com/insight-and-intelligenceand153/top-20-best-selling-drugs-of-2012/77899775/?page=1 [Last accessed 17 April 2014]
   Google Scholar
• Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-8
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Herceptin European Public Assessment Report. European Medicines Agency, 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf [Last accessed 27 October 2014]
   Google Scholar
• Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
   PubMed Web of Science ®Google Scholar
• Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3 open-label multicentre randomised trial. Lancet Oncol 2012;13:869-78
   PubMed Web of Science ®Google Scholar
• Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-17
   PubMed Web of Science ®Google Scholar
• Guideline on similar biological medicinal products [draft guidance]. European Medicines Agency. 2013; Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf [Last accessed 30 March 2014]
   Google Scholar
• What you need to know about biosimilar medicinal products. A consensus information document. European Commission. 2013. Available from: ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf [Last accessed 30 March 2014]
   Google Scholar
• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012;22:3-13
   PubMed Web of Science ®Google Scholar
• Revers L, Furczon E. An introduction to biologics and biosimilars. Part II: subsequent entry biologics: Biosame or biodifferent? Can Pharmacists J 2010;143:184-91
   Google Scholar
• Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. European Medicines Agency. 2012. Available at www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf [Last accessed 30 March 2014]
   Google Scholar
• Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. European Medicines Agency. 2012. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf [Last accessed 30 March 2014]
   Google Scholar
• Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency. 2006. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf [Last accessed 30 March 2014]
   Google Scholar
• Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency. 2006. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf [Last accessed 30 March 2014]
   Google Scholar
• Cortes J, Curigliano G, Dieras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 2014;144:233-9
   PubMed Web of Science ®Google Scholar
• Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic brease cancer. J Clin Oncol 2008;26:1987-92
   PubMed Web of Science ®Google Scholar
• Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72
   PubMed Web of Science ®Google Scholar
• Cary LA, Winer EP. Defining success in neoadjuvant breast cancer trials. Lancet 2014;384:115-16
   PubMed Web of Science ®Google Scholar
• Guideline on good pharmacovigilance practices (GVP). European Medicines Agency. 2012. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500123202.pdf [Last accessed 28 April 2014]
   Google Scholar
• European Commission Directive 2012/52/EU. Available from: ec.europa.eu/health/cross_border_care/docs/impl_directive_presciptions_2012_en.pdf [Last accessed 28 April 2014]
   Google Scholar
• Mellstedt H. Clinical considerations for biosimilar antibodies. Eur J Cancer Suppl 2013;11:1-11
   Google Scholar
• Remsima European Public Assessment Report. European Medicines Agency, 2013. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf [Last accessed 12 April 2014]
   Google Scholar
• Jackisch C, Scappaticci FA, Heinzmann D, et al. Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Future Oncol 2014;28:1-11
   Google Scholar
• Im Y-H, Odarchenko P, Grecea D, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol 2013;31(suppl):Abstract 629
   Google Scholar
• Celltrion’s Herzuma (trastuzumab) receives Korea MFDS approval. Celltrion, 2014. Available at www.celltrion.com/en/company/notice_view.asp?idx=425&code=ennews&intNowPage=1&menu_num=&align_year=all [Last accessed 21 April 2014]
   Google Scholar
• Indian court issues injunction on Biocon, Mylan’s Herceptin biosimilars after challenge by Roche. First World Pharma, 2014. Available from: www.firstwordpharma.com/node/1185990#axzz35RaF79J4 [Last accessed 10 May 2014]
   Google Scholar
• A safety and efficacy study of BCD-022 with paclitaxel compared to Herceptin with paclitaxel in HER2-positive metastatic breast cancer patients. U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT01764022 [Last accessed 10 May 2014]
   Google Scholar
• Amgen’s master plan to generate biosimilar blockbusters. Seeking Alpha. 2013. Available from: seekingalpha.com/article/1275871-amgens-master-plan-to-generate-biosimilar-blockbusters [Last accessed 10 May 2014]
   Google Scholar
• Efficacy and safety study of ABP 980 compared with trastuzumab in subjects with HER2 positive early breast cancer (Lilac). U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT01901146 [Last accessed 29 June 2014]
   Google Scholar
• Genor Biopharma and BIOCND form partnership to develop Genor’s mAb biosimilars for international market. First World Pharma. 2013. Available from: www.firstwordpharma.com/node/1098751#axzz2hGQakQmt [Last accessed 10 May 2014]
   Google Scholar
• Yin D, Barker KB, Li R, et al. A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01). J Clin Oncol 2013;31(suppl):abstract 612
   Google Scholar
• A study of PF-05280014 [Trastuzumab-Pfizer] or Herceptin® [Trastuzumab-EU] plus paclitaxel in HER2 positive first line metastatic breast cancer treatment (REFLECTIONS B327-02). U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT01989676 [Last accessed 29 June 2014]
   Google Scholar
• Hospira wins Herceptin patent suit in UK, paving way for biosim. Fierce Pharma. 2014. Available from: www.fiercepharma.com/story/hospira-wins-herceptin-patent-suit-uk-paving-way-biosim/2014-04-10 [Last accessed 30 June 2014]
   Google Scholar
• Dr Reddy’s, Intas to tap India’s Herceptin market. Business Standard. 2013. Available from: www.business-standard.com/article/companies/dr-reddy-s-intas-to-tap-india-s-herceptin-market-113082000798_1.html [Last accessed 10 May 2014]
   Google Scholar
• Biosimilars: 10 drugs to watch. Genetic Engineering & Biotechnology News. 2013. Available from: www.genengnews.com/keywordsandtools/print/3/31123/ [Last accessed 10 May 2014]
   Google Scholar
• A study to compare the effect of SB3 and Herceptin® in women with HER2 positive breast cancer. U.S. National Institutes of Health. 2014. Available from: clinicaltrials.gov/ct2/show/NCT02149524 [Last accessed 29 June 2014]
   Google Scholar
• Study of Cipterbin®, used alone or with vinorelbine in patients with HER2/neu-overexpressed metastatic breast cancer. U.S. National Institutes of Health. 2011. Available from: clinicaltrials.gov/ct2/show/NCT01439191 [Last accessed 29 June 2014]
   Google Scholar
• Choy E, Jacobs IA. Biosimilar safety considerations in clinical practice. Semin Oncol 2014;41:S3-14
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
   PubMed Web of Science ®Google Scholar